AKT1 and pancreatic neoplasm: Having demonstrated the utility of the Akt-FRET biosensor mouse in assessing aberrant AKT activity when a tumor suppressor is lost in pancreatic cancer, we went on to additionally show the effect of an activating mutation of PI3K upstream of AKT signaling in the context of immunodeficiency.